GlassScriptPhysician profile
Sanjay G Kavathia
NPI 1124078142
$13,137.14
in general payments reported to CMS, 2019-2025
44 companies · $1,803 in 2025
The $1,803 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,839 · 2020: $1,598 · 2021: $1,655 · 2022: $2,173 · 2023: $2,267 · 2024: $1,802 · 2025: $1,803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,811 · Education: $61.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,810.50 |
| Education | $61.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,834.01 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $2,045.85 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $894.37 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $884.39 | 2021-2025 | |
| Lilly USA, LLC | $636.76 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $597.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $519.71 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.08 | 2019-2025 | Jardiance, Ofev, Synjardy |
| Pfizer INC. | $336.10 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $298.87 | 2019-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $275.37 | 2023-2025 | Gemtesa, Myfembree |
| Glaxosmithkline, LLC. | $246.40 | 2019-2023 | Trelegy Ellipta |
| Amarin Pharma, INC. | $221.81 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $209.41 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $206.73 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjay Kavathia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.